About US
Contact us
-
Mylan expands cancer drug recall on particle contamination worriesCompanies are eyeingsterile injectable drugsfor growth, but the formulas are notoriously tricky to manufacture. Mylan ($MYL) has found that out the hard way, and it's now expanding a recall of cancer2015/6/10
-
Does brand + generic really add up? Sandoz, Actavis execs count the waysThese days, companies are increasingly looking to put both branded and generic meds under one roof. And Peter Goldschmidt, the U.S. president of Novartis' ($NVS) Sandoz unit, doesn't know why they did2015/6/10
-
Top Novartis brass backs results-based drug pricingNovartis ($NVS) CEO Joe Jimenez and Chairman Joerg Reinhardt sang the same tune on drug prices in separate interviews over the weekend, backing performance-based drug deals while pointing the finger a2015/6/9
-
How to avoid the 'magic pill' issue with weight loss meds? Honesty, journal saysWeight Watchers figured it out and so did "The Biggest Loser." Dieting and exercise to lose weight is more effective when done with support. Real research has proven the same thing, and weight-loss dr2015/6/9
-
Big data tells J&J that recent grads are more loyal than experienced hiresDrugmakers are increasingly using big data analysis to reap better insights into drug development. But the "people analytics team" at drugmaker Johnson & Johnson ($JNJ) turned the technique on emp2015/6/8
-
Merck launches Sivextro in U.K.Merck ($MRK) is launching Sivextro, the newly approved antibiotic it picked up in its $9.5 billion buyout ofCubist, in the U.K.Pharmafilereports it is the first oral treatment to be released in the ox2015/6/8
-
Fresh off Novartis consumer deal, GSK slices off 350 workers to hit cost-squeezing targetsNow that it's teamed up with Novartis' ($NVS) consumer health unit to form an industry-leading joint venture, GlaxoSmithKline's ($GSK) OTC business is bigger than ever. But its payroll is about to get2015/6/5
-
Sanofi bags 'breakthrough' tag for new Genzyme rare disease medSanofi's ($SNY) rare disease-focused unitGenzymepicked up theFDA's coveted breakthrough-therapy designation for a drug designed to treat a form of Niemann-Pick disease. The French drugmaker is set for2015/6/5
-
Jury sides with Merck and its execs in gender-bias caseMerck & Co. ($MRK) won the day in a gender discrimination suit on Tuesday, as a federal jury found that former employee Kerri Colicchio failed to prove she was discriminated against because of h2015/6/4
-
Merck's 'landmark' Zetia data hits NEJM, giving a boost to all LDL-fighting medsThe nitty-gritty on Merck & Co.'s ($MRK)Zetiaoutcomes trial is now revealed--and it's not just good news for the cholesterol-fighting drug and its combo-pill sister Vytorin. It's good for all high2015/6/4